Health care expenditures for Medicaid‐covered males with haemophilia in the United States, 2008
- 21 December 2011
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 18 (2) , 276-283
Abstract
Summary. Although haemophilia is an expensive disorder, no studies have estimated health care costs for Americans with haemophilia enrolled in Medicaid as distinct from those with employer‐sponsored insurance (ESI). The objective of this study is to provide information on health care utilization and expenditures for publicly insured people with haemophilia in the United States in comparison with people with haemophilia who have ESI. Data from the MarketScan® Medicaid Multi‐State, Commercial and Medicare Supplemental databases were used for the period 2004−2008 to identify cases of haemophilia and to estimate medical expenditures during 2008. A total of 511 Medicaid‐enrolled males with haemophilia were identified, 435 of whom were enrolled in Medicaid for at least 11 months during 2008. Most people with haemophilia qualified for Medicaid based on ‘disability’. Average Medicaid expenditures in 2008 were $142,987 [median, $46,737], similar to findings for people with ESI. Average costs for males with haemophilia A and an inhibitor were 3.6 times higher than those for individuals without an inhibitor. Average costs for 56 adult Medicaid enrollees with HCV or HIV infection were not statistically different from those for adults without the infection, but median costs were 1.6 times higher for those treated for blood‐borne infections. Haemophilia treatment can lead to high costs for payers. Further research is needed to understand the effects of public health insurance on haemophilia care and expenditures, to evaluate treatment strategies and to implement strategies that may improve outcomes and reduce costs of care.Keywords
This publication has 8 references indexed in Scilit:
- Healthcare expenditures for males with haemophilia and employer‐sponsored insurance in the United States, 2008Haemophilia, 2011
- Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United StatesPediatric Blood & Cancer, 2009
- Medical Costs and Resource Utilization for Hemophilia Patients With and Without HIV or HCV InfectionJournal of Managed Care Pharmacy, 2007
- The economic impact of factor VIII inhibitors in patients with haemophiliaHaemophilia, 2004
- Who Cares for Medicaid-Enrolled Children With Chronic Conditions?Pediatrics, 2001
- Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators.2000
- Health Care Utilization by Children With Chronic Illnesses: A Comparison of Medicaid and Employer-insured Managed CarePediatrics, 1998
- Mortality in the Uninsured Compared With That in Persons With Public and Private Health InsuranceArchives of internal medicine (1960), 1994